Market Closed -
Nasdaq
21:00:00 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
27.04
USD
|
+1.65%
|
|
+10.28%
|
-16.75%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,383
|
3,039
|
2,097
|
2,186
|
3,348
|
2,815
|
-
|
-
|
Enterprise Value (EV)
1 |
1,383
|
3,039
|
2,097
|
2,186
|
2,980
|
2,156
|
2,067
|
2,815
|
P/E ratio
|
15.7
x
|
30.8
x
|
22.2
x
|
23.3
x
|
34.6
x
|
28.1
x
|
21
x
|
10.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.51
x
|
8.59
x
|
5.73
x
|
5.44
x
|
6.94
x
|
4.45
x
|
3.98
x
|
2.96
x
|
EV / Revenue
|
4.51
x
|
8.59
x
|
5.73
x
|
5.44
x
|
6.18
x
|
3.41
x
|
2.92
x
|
2.96
x
|
EV / EBITDA
|
12.3
x
|
23.6
x
|
16.7
x
|
14
x
|
-
|
15.8
x
|
9.55
x
|
9.73
x
|
EV / FCF
|
10.2
x
|
20.2
x
|
12.5
x
|
-
|
23.5
x
|
13.8
x
|
10.9
x
|
-
|
FCF Yield
|
9.76%
|
4.96%
|
7.98%
|
-
|
4.26%
|
7.27%
|
9.16%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
114,281
|
116,173
|
105,934
|
107,650
|
103,081
|
104,112
|
-
|
-
|
Reference price
2 |
12.10
|
26.16
|
19.80
|
20.31
|
32.48
|
27.04
|
27.04
|
27.04
|
Announcement Date
|
20/02/20
|
08/02/21
|
15/02/22
|
28/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
306.5
|
353.9
|
366
|
401.9
|
482.4
|
632.1
|
707.9
|
951.9
|
EBITDA
1 |
112.3
|
128.7
|
125.5
|
155.9
|
-
|
136.8
|
216.5
|
289.2
|
EBIT
1 |
111.6
|
128.2
|
124.5
|
112.6
|
107.3
|
122.2
|
171.6
|
385
|
Operating Margin
|
36.41%
|
36.23%
|
34.01%
|
28.03%
|
22.24%
|
19.33%
|
24.24%
|
40.45%
|
Earnings before Tax (EBT)
1 |
116.7
|
131.6
|
125
|
116.2
|
124.6
|
133.7
|
181.7
|
392.5
|
Net income
1 |
94.18
|
106
|
112.5
|
101.3
|
105.5
|
109.1
|
147.7
|
313.9
|
Net margin
|
30.73%
|
29.96%
|
30.74%
|
25.2%
|
21.87%
|
17.26%
|
20.87%
|
32.97%
|
EPS
2 |
0.7700
|
0.8500
|
0.8900
|
0.8700
|
0.9400
|
0.9620
|
1.286
|
2.662
|
Free Cash Flow
1 |
135
|
150.7
|
167.4
|
-
|
126.9
|
156.8
|
189.2
|
-
|
FCF margin
|
44.06%
|
42.58%
|
45.75%
|
-
|
26.31%
|
24.8%
|
26.73%
|
-
|
FCF Conversion (EBITDA)
|
120.23%
|
117.07%
|
133.35%
|
-
|
-
|
114.61%
|
87.41%
|
-
|
FCF Conversion (Net income)
|
143.37%
|
142.16%
|
148.8%
|
-
|
120.29%
|
143.73%
|
128.1%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/02/20
|
08/02/21
|
15/02/22
|
28/02/23
|
15/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
98.82
|
93.69
|
103.4
|
101.7
|
103.1
|
105.7
|
117.7
|
123.6
|
135.4
|
146.8
|
155.2
|
162.1
|
168
|
167.2
|
173
|
EBITDA
|
36.95
|
37.82
|
42.15
|
42.68
|
33.2
|
26.17
|
29.77
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
36.66
|
26.77
|
31.43
|
31.93
|
22.5
|
14.85
|
29.58
|
31.18
|
31.67
|
29.5
|
29.07
|
30.95
|
33.89
|
34.04
|
37.85
|
Operating Margin
|
37.1%
|
28.57%
|
30.4%
|
31.39%
|
21.83%
|
14.06%
|
25.13%
|
25.22%
|
23.39%
|
20.09%
|
18.73%
|
19.1%
|
20.18%
|
20.35%
|
21.89%
|
Earnings before Tax (EBT)
1 |
36.74
|
26.85
|
32.06
|
33
|
24.28
|
18.43
|
32.93
|
36.38
|
36.81
|
34.99
|
31.66
|
33.53
|
35.81
|
37.3
|
41.15
|
Net income
1 |
32.05
|
22.8
|
27.4
|
34.55
|
16.55
|
15.81
|
27.36
|
31.17
|
31.14
|
27.51
|
26.18
|
27.68
|
29.83
|
29.6
|
32.74
|
Net margin
|
32.44%
|
24.33%
|
26.5%
|
33.96%
|
16.06%
|
14.96%
|
23.24%
|
25.22%
|
23%
|
18.74%
|
16.87%
|
17.08%
|
17.76%
|
17.7%
|
18.93%
|
EPS
2 |
0.2600
|
0.2000
|
0.2400
|
0.3000
|
0.1400
|
0.1400
|
0.2500
|
0.2800
|
0.2800
|
0.2500
|
0.2300
|
0.2440
|
0.2600
|
0.2750
|
0.3075
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/02/22
|
05/05/22
|
03/08/22
|
03/11/22
|
28/02/23
|
03/05/23
|
02/08/23
|
01/11/23
|
15/02/24
|
01/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
368
|
659
|
748
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
135
|
151
|
167
|
-
|
127
|
157
|
189
|
-
|
ROE (net income / shareholders' equity)
|
29.1%
|
23.7%
|
25%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
1.330
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.09
|
1.24
|
0.47
|
0.41
|
0.14
|
0.32
|
0.39
|
0.5
|
Capex / Sales
|
0.35%
|
0.35%
|
0.13%
|
0.1%
|
0.03%
|
0.05%
|
0.06%
|
0.05%
|
Announcement Date
|
20/02/20
|
08/02/21
|
15/02/22
|
28/02/23
|
15/02/24
|
-
|
-
|
-
|
Last Close Price
27.04
USD Average target price
43.6
USD Spread / Average Target +61.24% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.75% | 2.82B | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|